

Serum
Post-IVIg Serum
IV.3 F(ab) + Serum
Heparin + Serum
Heat Inactivated Serum
Post-Plasma Exchange
HD1
HD2
HD3
HD4
P1
P2
P3
P4
P5
P6
P7
25 % Aggregation
5 min

Fig. 1A



AUC
0
250
500
750
HD1
HD2
HD3
HD4
P2
P3
P4
P7
HD Serum (Vaccinated)
Serum
Post-IVIg Serum
IV.3 F(ab) + Serum
Heparin + Serum
Heat Inactivated Serum
ns
*

Fig. 1B



p1
p5
p6
ns
*
ns
ns
ns
*
ns
ns
*
ns
ns
AUC
0
250
500
750
Post-IVIg Serum
IV.3 F(ab) + Serum
Heparin + Serum
Heat Inactivated Serum
Post-plasma Exchange Serum

Fig. 1C



P3
P4
P5
P7
AUC
0
250
500
*
Vehicle (0.02% DMSO)
Rilzabrutinib 0.5 μM

Fig. 2B



Serum
Vehicle
Rilzabrutinib
5 min
25 % Aggregation

Fig. 2A